The Effects of Zonisamide on Alcohol Dependence

NCT00406692 | Completed Phase 2 Results DMC

• 1 other identifier: H-25544
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

In this study the influence of zonisamide administration over a 13 week period on alcohol consumption in alcoholic (alcohol dependent) subjects will be examined. The dose of zonisamide given to subjects will be slowly increased over a period of several weeks. They will receive a full dose over a 5 week period. This will be a pilot study in which all of the subjects will only receive zonisamide. A primary objective of this study is to determine the possible size of the effect that zonisamide administration has on drinking (i.e. drinks consumed per day) to allow us to plan for a larger clinical trial of the effects of zonisamide on alcohol dependence.

Conditions

Alcoholism

Keywords

Zonisamide; Alcoholism; Alcohol

Outcome Measures

Primary Outcomes (2)

• The Weekly Mean Number of Standard Drinks Consumed Per Day at Baseline and Treatment Phase

  The mean daily standard alcoholic drinks were determined for the baseline period and each treatment week as a measure of alcohol intake. One standard drink=14g of alcohol. Mean value is the difference between mean standard drinks for the baseline period and week 12 of the study.

  Baseline and Week 12

• Difference in Mean Words for the Phonetic Portion of the Controlled Word Association Test (COWAT).

  Subjects were asked to generate as many words as possible starting with a particular letter over a 60 second period. Three letters were used for each sessions. Values shown are the differences between values obtained for the baseline and week 12 test session.

  Week 0- Baseline and Week 12

Secondary Outcomes (1)

• Symbol Digit Modalities Test (DSMT)

  Baseline, Week 12

Study Arms (1)

Zonisamide

EXPERIMENTAL

In open-label non-placebo controlled trial subjects are treatment with zonisamide 400 mg during the maintenance phase of this study

Drug: Zonisamide

Interventions

Zonisamide DRUG

Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.

Zonisamide

Eligibility Criteria

• Age: 21 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• To be admitted into this study patients must meet the following criteria:
• DSM IV TR Diagnosis of Alcohol Dependence; minimal level of 14 drinks per week for women or 21 drinks per week for men over a 28 day consecutive period during the 90 day period prior to the screening session.
• Male or Female 21-64 years of age.
• Able to provide informed consent and comprehend study procedures.
• Negative urine toxicological screen for opioids, psychomotor stimulants, sedative-hypnotics, and cannabinoids. If the urine tox screen was positive for any substance it may be repeated within two weeks.
• Score of \>8 on the Alcohol Use Disorder Identification Test (AUDIT) during screening.
• Must be suitable for outpatient management of alcoholism.
• Express desire to stop drinking or reduce alcohol consumption with a possible long-term goal of abstinence.
• Provide contact information for themselves or an alternate contact that the staff will call in case of missed appointment.
• Women must be postmenopausal for at least one year, be surgically sterile, be using an effective method of birth control (e.g. contraceptive injection, intrauterine device, spermicide with barrier, contraceptive patch, contraceptive ring, male partner sterilization, oral contraceptives) or completely abstinent (and agree to use one of the above mentioned methods of contraception if sexual activity is ever initiated).
• Must be able to take oral medications, adhere to the regimen and be willing to return for follow up visits.
• Must have breath alcohol concentration of no more than 0.01% when the informed consent is provided and the consent form is signed.
• Must have resided at the same address for at least 3 months.

You may not qualify if:

• Patients meeting the following criteria will be excluded from the study:
• Dependent on or extensive abuse of drugs or substances other than ethanol, nicotine, or caffeine.
• DSM IV-TR diagnosis of any current Axis I diagnosis other than alcohol dependence, nicotine dependence, or caffeine dependence that in the opinion of the study physicians might require intervention with either pharmacological or non-pharmacological therapy that will interfere with the course of the study.
• Receiving inpatient or outpatient treatment for alcohol dependence (with the exception of AA or other self-help groups) within 4 weeks prior to enrollment into this study.
• Subjects with a score of 10 or greater on the CIWA-Ar (a withdrawal scale) on first or second visits.
• Currently being treated with acamprosate, disulfiram or naltrexone.
• Currently being treated with any of the following medications: a) Antipsychotic agents- including clozapine, risperidone, quetiapine, haloperidol b) Antimanic or anticonvulsant agents- including lithium carbonate, phenytoin, phenobarbital, carbamazepine, topiramate, valproic acid, divalproex, tiagabine c) Sedative-hypnotic or antianxiety agents-including triazolam, temazepam, zolpidem, zalepron, buspirone, alprazolam, diazepam, clonazepam, oxazepam, lorazepam d) chronic opioid treatment- including methadone, buprenorphine, oxycodone, morphine e) Psychomotor stimulants- amphetamine derivatives, methylphenidate
• Subjects who are legally mandated to participate in an alcohol treatment program
• Use of any medication known to inhibit or induce cytochrome P450 3A4 enzymes including macrolide antibiotics, fluoxetine, and carbamazepine.
• Subjects who have attempted suicide or who have had suicidal ideation within 30 days of their first visit as assessed using responses from the SCID and Hamilton Depression scale.
• Subjects with renal disease (including severe infection and cancer), impaired renal clearance (CrCl less than 50 ml/min), or history of kidney stones.
• Subjects with AST or ALT \>3 times the upper limit of the normal range during screening.
• History of significant neurological disorder, including a history of seizures, stroke, dementia, multiple sclerosis, Parkinson's disease, brain tumors, or encephalitis.
• Subjects who are pregnant (as assessed by serum HCG) or lactating.
• Subjects known to have clinically significant medical conditions. These may include: symptomatic CAD or PVD, malignancy or history of malignancy in the last 5 years, significant pulmonary disease or endocrinological disorders.

Sponsors & Collaborators

• Boston University: lead

Study Sites (1)

Boston University School of Medicine

Boston, Massachusetts, 02118, United States

Location

MeSH Terms

Conditions

Alcoholism

Interventions

Zonisamide

Condition Hierarchy (Ancestors)

Alcohol-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Sulfonamides; Amides; Organic Chemicals; Sulfones; Sulfur Compounds; Isoxazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Limitations and Caveats

Limitations of this trial include lack of a placebo controlled arm and small sample size.

Results Point of Contact

• Title: Clifford Knapp, PhD
• Organization: Boston University

cknapp@bu.edu

617-414-1990

Study Officials

• Clifford Knapp, PhD

  Boston University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 30, 2006
• First Posted: December 4, 2006
• Study Start: November 1, 2006
• Primary Completion: August 1, 2008
• Study Completion: November 1, 2009
• Last Updated: May 11, 2010
• Results First Posted: May 6, 2010

Record last verified: 2010-05

Locations

US (1)